Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
3.000
-0.050 (-1.64%)
Mar 9, 2026, 2:15 PM EDT - Market open
Gain Therapeutics Employees
As of December 31, 2024, Gain Therapeutics had 25 total employees, including 23 full-time and 2 part-time employees. The number of employees decreased by 7 or -21.88% compared to the previous year.
Employees
25
Change (1Y)
-7
Growth (1Y)
-21.88%
Revenue / Employee
n/a
Profits / Employee
-$775,670
Market Cap
115.39M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Codexis | 188 |
| Gossamer Bio | 145 |
| Inovio Pharmaceuticals | 134 |
| Precision BioSciences | 67 |
| Equillium | 35 |
| Oncolytics Biotech | 28 |
| Genelux | 24 |
| Black Diamond Therapeutics | 24 |
GANX News
- 18 days ago - Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week - GlobeNewsWire
- 2 months ago - Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 - GlobeNewsWire
- 2 months ago - Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease - GlobeNewsWire
- 2 months ago - Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease - GlobeNewsWire
- 3 months ago - Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025 - GlobeNewsWire
- 4 months ago - Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients - Seeking Alpha